Correction: Balleza Alejandri et al. Empagliflozin and Dapagliflozin Improve Endothelial Function in Mexican Patients with Type 2 Diabetes Mellitus: A Double-Blind Clinical Trial. <i>J. Cardiovasc. Dev. Dis.</i> 2024, <i>11</i>, 182

Gelijkaardige items

• Divergent electrophysiologic action of dapagliflozin and empagliflozin on ventricular and atrial tachyarrhythmias in isolated rabbit hearts
  door: Julian Wolfes, et al.
  Gepubliceerd in: (2024-02-01)
• Gliflozins in Practice: Real-Life Use of Dapagliflozin and Empagliflozin in HFrEF Versus Clinical Trial Data
  door: Massimo Mapelli, et al.
  Gepubliceerd in: (2026-03-01)
• Corrigendum: Divergent electrophysiologic action of dapagliflozin and empagliflozin on ventricular and atrial tachyarrhythmias in isolated rabbit hearts
  door: Julian Wolfes, et al.
  Gepubliceerd in: (2025-02-01)
• Head-to-Head in Heart Failure: Comparative Insights on Empagliflozin and Dapagliflozin
  door: Dragos Cozma, et al.
  Gepubliceerd in: (2025-10-01)
• Assessing the Efficacy and Safety of Dapagliflozin and Empagliflozin as an Add-on Therapy for Lowering Glycated Hemoglobin and Weight in Type 2 Diabetes Mellitus Patients
  door: Mahima Makhija, Alka Bansal, Lokendra Sharma, Punam Jakhar, Susheel Kumar, Ashish Agrawal
  Gepubliceerd in: (2025-06-01)